Ownership and insider activity for Actinium Pharmaceuticals, Inc. (ATNM): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT.
Price
| Price | $1.24 |
| Market Cap | $39M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-03 | Kamal Adeela | |||
| 2026-09-03 | Kamal Adeela | 120,000 | $120K | |
| 2026-09-03 | Heeger Steffen Wilhem | |||
| 2026-09-03 | Heeger Steffen Wilhem | 250,000 | $288K | |
| 2026-09-02 | Shetty Ajit | A-Award | 92,400 | $92K |
| 2026-09-02 | Shetty Ajit | A-Award | 61,600 | |
| 2026-09-02 | Nicholson, C. David | A-Award | 94,200 | $94K |
| 2026-09-02 | Nicholson, C. David | A-Award | 62,800 | |
| 2026-09-02 | Almenoff June Sherie | A-Award | 27,000 | $27K |
| 2026-09-02 | Almenoff June Sherie | A-Award | 18,000 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.5M | $17.4M | $13.7M | $9.3M | $63.6M | $77.8M | $108.9M | $76.7M | $72.9M | $48.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $22.4M | $17.8M | $14.3M | $10.1M | $64.9M | $79.7M | $110.9M | $78.3M | $74.5M | $49.4M |
| Property, Plant & Equipment | $88549 | $57350 | $118799 | $1.1M | $1.0M | $639000 | $2.9M | $2.9M | $2.1M | $2.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $22.5M | $18.3M | $14.9M | $11.7M | $66.4M | $80.4M | $114.2M | $81.4M | $76.9M | $51.8M |
| Accounts Payable | $4.2M | $4.7M | $5.8M | $4.6M | $4.3M | $5.5M | $10.1M | $8.0M | $7.6M | 0 |
| Short-term Debt | 0 | 0 | $249239 | $381000 | $427000 | 0 | 0 | $541000 | 0 | $722000 |
| Total Current Liabilities | $4.5M | $4.7M | $6.1M | $5.3M | $4.8M | $6.8M | $10.6M | $8.5M | $8.1M | $8.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.5M | $4.7M | $6.1M | $6.0M | $5.1M | $6.8M | $47.7M | $45.1M | $44.1M | $43.9M |
| Retained Earnings | -$136.6M | -$163.2M | -$186.9M | -$208.8M | -$231.0M | -$255.7M | -$288.8M | -$337.6M | -$375.8M | -$409.7M |
| Total Equity | $18.0M | $13.7M | $8.8M | $5.6M | $61.3M | $73.5M | $66.5M | $36.4M | $32.8M | $7.8M |
| Total Debt | 0 | 0 | $262593 | $1.4M | $738000 | $310000 | $2.6M | $2.1M | $1.6M | $1.7M |
| Net Debt | -$20.5M | -$17.4M | -$13.4M | -$7.8M | -$62.9M | -$77.5M | -$106.3M | -$74.6M | -$71.3M | -$46.3M |
| Working Capital | $17.9M | $13.2M | $8.3M | $4.7M | $60.2M | $72.9M | $100.3M | $69.8M | $66.4M | $41.4M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 4.08 |
Profitability
| Return on Equity | 83.42% |
| Return on Invested Capital | 30.20% |
| Return on Assets | 28.16% |
| Gross Margin | 101.13% |
| Operating Margin | 27.23% |
| Net Margin | 32.23% |
Related companies: ANVS · FGEN · KZR · LVTX · OKUR · PDSB · RVPH
Explore sector: Healthcare · Biotechnology
More sections of ATNM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks